Antibody-drug conjugate (ADC) specialist Seagen has claimed its ... as a second-line monotherapy for recurrent or metastatic cervical cancer. The accelerated approval for Tivdak (tisotumab vedotin ...

This morning, the Japanese drugmaker reported updated clinical results from two clinical trials of its HER3-targeted ADC patritumab deruxtecan in metastatic breast cancer and non-small cell lung ...

Japan approves Tivdak, the first ADC for cervical cancer, after Phase 3 trial shows a 30% reduction in death risk vs. chemotherapy. The trial of 502 patients showed Tivdak improved median overall ...

Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced or recurrent cervical cancer that progressed on or following ...

The drug has been specifically authorised to treat adults experiencing disease progression on or after systemic therapy, and is now the first antibody-drug conjugate (ADC) to be approved in the EU for ...

Although ovarian cancer ranks third among gynecologic malignancies in incidence, behind cervical and endometrial ... As an anti-HER2 ADC, preliminary findings from IBI354 have demonstrated ...

Tivdak is the first and only antibody-drug conjugate (ADC) to be approved for cervical cancer in Japan. The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated ...